TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35446934

Group type: EXPERIMENTAL
Intervention: CD19-CAR T-cell therapy
Number of subjects: 12
Study: 35446944

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg BID day 1, 800 mg BID days 2-10)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 35447145

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream, applied 3 times a week for 16 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 24
Study: 35448002

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg daily during HSRT, adjuvant d1-14 every 3 weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT) (25.0 Gy in 5 fractions)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 5
Study: 35448016

Group type: EXPERIMENTAL
Intervention: Music interventions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Baseline stress
Number of subjects: 200
Study: 35448159

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 182
Study: 35449010

Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (PoCUS) (≤120 min)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Late point-of-care ultrasound (PoCUS) (>120 min)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (PoCUS)
Number of subjects: 888
Study: 35449028

Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 40000
Study: 35449030

Group type: EXPERIMENTAL
Intervention: BioNTech/Pfizer (BNT162b2, n=34)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Moderna (mRNA-1273, n=20)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: AstraZeneca (ChAdOx1 nCoV-19, n=32)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Confirmed SARS-CoV-2 infection (n=19)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Pre-pandemic group (n=20)
Number of subjects: 86
Study: 35449043

Group type: EXPERIMENTAL
Intervention: Specific physical activities
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Frequency of exposure to specific activities
Number of subjects: 550
Study: 35449071

Group type: EXPERIMENTAL
Intervention: Subtype A (16% one-year mortality)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Subtype B (34% one-year mortality)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Subtype B (adjusted for long-term risk factors)
Number of subjects: 467
Study: 35449189

Group type: EXPERIMENTAL
Intervention: Iontophorised Acetylcholine (ACh) at 5 concentrations (0.0001% to 1%) administered via three consecutive pulses of 0.02 mA for 10 min each
Number of subjects: 15
Study: 35449247

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion group (400 mL of carbohydrate-containing fluid two hours prior to surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting group (fasted from midnight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 35449533

Group type: EXPERIMENTAL
Intervention: Guideline directed oral anticoagulants (OACs) including direct oral anticoagulants (DOACs)
Number of subjects: 379
Study: 35449578

Group type: EXPERIMENTAL
Intervention: S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy (61.2 Gy delivered in 34 fractions)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy
Number of subjects: 105
Study: 35450151

Group type: EXPERIMENTAL
Intervention: Care as defined by their physician, with study visits scheduled every 6 months.
Number of subjects: 0
Study: 35450196

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BDP/FF (beclometasone dipropionate/formoterol fumarate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDP/FF/G
Number of subjects: 0

Group type: COMPARATOR
Intervention: BDP/FF
Number of subjects: 0
Study: 35450477

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35450679

Group type: EXPERIMENTAL
Intervention: Unplanned DAPT discontinuation
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Unplanned DAPT discontinuation ≥3 weeks after PCI
Number of subjects: 8582

Group type: COMPARATOR
Intervention: Planned DAPT discontinuation
Number of subjects: 8582

Group type: COMPARATOR
Intervention: HPR on clopidogrel
Number of subjects: 8582
Study: 35450750

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)] levels
Number of subjects: 312

Group type: COMPARATOR
Intervention: High-intensity statin use
Number of subjects: 312

Group type: COMPARATOR
Intervention: On-treatment low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Lipoprotein(a) levels
Number of subjects: 312
Study: 35450817

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-intensity chemotherapy
Number of subjects: 45
Study: 35450906

Group type: EXPERIMENTAL
Intervention: D-REM programme (Community paramedicine programme)
Number of subjects: 70
Study: 35450966

Group type: EXPERIMENTAL
Intervention: Baseline CT perfusion (CTP) ischemic core estimates using rCBF <30%
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Follow-up diffusion-weighted imaging (DWI) lesions
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Use of rCBF <20% threshold for estimating ischemic core
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Volumetric correlation between ischemic core estimate and follow-up imaging
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Significant overestimation of ischemic core volume
Number of subjects: 101
Study: 35451010

Group type: EXPERIMENTAL
Intervention: Endoluminal vacuum therapy (EVT) using Eso-Sponge®
Number of subjects: 102
Study: 35451040

Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE)
Number of subjects: 298
Study: 35451176

Group type: EXPERIMENTAL
Intervention: Voxelotor treatment for up to 48 weeks
Number of subjects: 45
Study: 35451199

Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulforaphane + CB-5083
Number of subjects: 0

Group type: COMPARATOR
Intervention: CB-5083
Number of subjects: 0
Study: 35451488

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35451899

Group type: EXPERIMENTAL
Intervention: ATTRv with autonomic dysfunction
Number of subjects: 2922

Group type: COMPARATOR
Intervention: ATTRv without autonomic dysfunction
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: ATTRwt with autonomic dysfunction
Number of subjects: 2922

Group type: COMPARATOR
Intervention: ATTRwt without autonomic dysfunction
Number of subjects: 2922
Study: 35451922

Group type: EXPERIMENTAL
Intervention: Multiple-Breath Washout
Number of subjects: 0
Study: 35451989

Group type: EXPERIMENTAL
Intervention: Cardiac imaging based on cardiac magnetic resonance and echocardiography
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 150
Study: 35452178

Group type: EXPERIMENTAL
Intervention: Supportive care with transfusions and surgical interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular hematology care with visits at least every 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer disease-modifying therapies being developed and studied
Number of subjects: 0
Study: 35452195

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study: 35452519

Group type: EXPERIMENTAL
Intervention: Leronlimab (CCR5-binding antibody), specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35452785

Group type: EXPERIMENTAL
Intervention: Adolescents with depression pre-pandemic
Number of subjects: 166

Group type: COMPARATOR
Intervention: Healthy volunteers (HVs) pre-pandemic
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adolescents with depression during the pandemic
Number of subjects: 166

Group type: COMPARATOR
Intervention: Healthy volunteers (HVs) during the pandemic
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adolescents with depression
Number of subjects: 166
Study: 35452808

Group type: EXPERIMENTAL
Intervention: Parsley drink containing apigenin-7-O-(2"-O-apiosyl)glucoside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apigenin
Number of subjects: 0
Study: 35453059

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed during hospitalization
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed 2-3 months after discharge
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) score
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Total number of B-lines
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) findings in patients with ARDS
Number of subjects: 71
Study: 35453064

Group type: EXPERIMENTAL
Intervention: Perampanel (median maximum dose 6.0 mg/day)
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1451
Study: 35454839

Group type: EXPERIMENTAL
Intervention: Noninvasive physical plasma (NIPP) treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NIPP treatment
Number of subjects: 20
Study: 35455592

Group type: EXPERIMENTAL
Intervention: Sevoflurane exposure before 45 weeks corrected gestational age
Number of subjects: 139
Study: 35455660

Group type: EXPERIMENTAL
Intervention: Intravenous antiarrhythmic agents (amiodarone, vernakalant, ibutilide)
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Atrial flutter
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Duration of symptoms associated with AF (<24 h)
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Absence of previous electrical cardioversion
Number of subjects: 3053
Study: 35456277

Group type: EXPERIMENTAL
Intervention: Neurological music therapy for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 35456481

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35457335

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention for 12 weeks
Number of subjects: 62
Study: 35459113

Group type: EXPERIMENTAL
Intervention: Community health worker assessment aided by mHealth
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Community health worker assessment for danger signs (excluding hypothermia)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 273
Study: 35459238

Group type: EXPERIMENTAL
Intervention: Navigator-supported remote symptom monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 35459672

Group type: EXPERIMENTAL
Intervention: Socially disadvantaged patients (EPICES score ≥30.17)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without specified social vulnerability
Number of subjects: 0
Study: 35459680

Group type: EXPERIMENTAL
Intervention: Pulse oximeter measurements (preductal and postductal)
Number of subjects: 2000
Study: 35459679

Group type: EXPERIMENTAL
Intervention: Early palliative care acceptance group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Early palliative care refusal group (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (n=40)
Number of subjects: 40
Study: 35459718

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Statin and ezetimibe
Number of subjects: 462
Study: 35459929

Group type: EXPERIMENTAL
Intervention: Low serum BDNF (sBDNF) levels
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Diabetes and low sBDNF levels or BDNF Met/Met genotype
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Diabetes with sBDNF in the lowest tertile or BDNF Met/Met genotype
Number of subjects: 969
Study: 35460043

Group type: EXPERIMENTAL
Intervention: Lixisenatide (10 μg sc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35460313

Group type: EXPERIMENTAL
Intervention: Pain management at haemophilia treatment centres (HTC)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Management of depression/anxiety at haemophilia treatment centres (HTC)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 343

Group type: COMPARATOR
Intervention: HTC survey responses
Number of subjects: 343
Study: 35460412

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation during IUI treatment
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Suboptimal ovarian response
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Serum AMH
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: BMI and serum basal FSH
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Age, BMI, and serum FSH
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: AMH addition to prediction models
Number of subjects: 492
Study: 35460497

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar® Gel); 80 U subcutaneously twice weekly for 12 weeks
Number of subjects: 15
Study: 35460583

Group type: EXPERIMENTAL
Intervention: Access to medical insurance
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Having a mobile phone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: History of more severe childhood trauma
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall well-being
Number of subjects: 99
Study: 35460850

Group type: EXPERIMENTAL
Intervention: Young-old patients (60-69 years)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Middle-old patients (70-79 years)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Very old patients (≥80 years)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Overall mortality by age group
Number of subjects: 2337
Study: 35460884

Group type: EXPERIMENTAL
Intervention: HeartLogic multisensor index and alerts
Number of subjects: 200
Study: 35460882

Group type: EXPERIMENTAL
Intervention: Lonely (total UCLA Three-Item Loneliness Scale score ≥5)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Frailty (Liver Frailty Index ≥4.4)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Not working
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Not in a committed partnership
Number of subjects: 454
Study: 35460976

Group type: EXPERIMENTAL
Intervention: Nirogacestat (PF-0308401)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-secretase inhibitor AL102
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-catenin inhibitor Tegavivint (BC2059)
Number of subjects: 0
Study: 35461007

Group type: EXPERIMENTAL
Intervention: Neuro-prosthetic leg use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35461085

Group type: EXPERIMENTAL
Intervention: Opioid misuse
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Existing evidence-based substance use interventions
Number of subjects: 3794
Study: 35461262

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) scopolamine administered over the course of 2 weeks with three blinded infusions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered over the course of 2 weeks with three blinded infusions.
Number of subjects: 0
Study: 35461300

Group type: EXPERIMENTAL
Intervention: Evidence-based behavioral interventions (EBI) for methamphetamine use
Number of subjects: 600
Study: 35462388

Group type: EXPERIMENTAL
Intervention: Pre-ECT evaluation practices including complete blood count, serum electrolytes, renal function analysis, cardiovascular assessment, psychiatric scales, and cognitive assessment.
Number of subjects: 18
Study: 35462754

Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Breast MRI (CE-BMRI)
Number of subjects: 778

Group type: COMPARATOR
Intervention: X-ray Mammography (XRM)
Number of subjects: 778
Study: 35463013

Group type: EXPERIMENTAL
Intervention: AKI1
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: AKI2
Number of subjects: 1526

Group type: COMPARATOR
Intervention: AKI1 and AKI2
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Injury-based molecular scores
Number of subjects: 1526
Study: 35463015

Group type: EXPERIMENTAL
Intervention: AIDA International Registry
Number of subjects: 290
Study: 35463344

Group type: EXPERIMENTAL
Intervention: Modified Prostate Health Index Density (mPHI)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Prostate Health Index (PHI)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Prostate Health Index Density (PHID)
Number of subjects: 278
Study: 35463750

Group type: EXPERIMENTAL
Intervention: Donor-derived Cell Free DNA (dd-cfDNA) levels measured in patients undergoing routine coronary angiography
Number of subjects: 94
Study: 35463775

Group type: EXPERIMENTAL
Intervention: Novel HAMIOT risk score
Number of subjects: 12043
Study: 35463834

Group type: EXPERIMENTAL
Intervention: Health Behavior in School-aged Children (HBSC) questionnaire
Number of subjects: 50

Group type: COMPARATOR
Intervention: Travel diary
Number of subjects: 50
Study: 35463896

Group type: EXPERIMENTAL
Intervention: Primary in-the-bag intraocular lens (IOL) implantation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Posterior capsulorhexis or capsulectomy with a diameter of 3.0 to 4.0 mm
Number of subjects: 23
Study: 35463939

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated patients with rCDI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Effective treatment (including rescue FMT)
Number of subjects: 64
Study: 35464004

Group type: EXPERIMENTAL
Intervention: Myosteatosis diagnosed during acute COVID-19
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Myosteatosis (lowest sex- and age-specific tertile of SM-RA)
Number of subjects: 97
Study: 35464483

Group type: EXPERIMENTAL
Intervention: Th2-oriented immune serum from alum-adjuvanted S1 subunit vaccines
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Th2-oriented immune serum from inactivated SARS-CoV-2 vaccination
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study: 35465706

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (ART-NQ) single doses of 20 mg/kg for artemisinin and 8 mg/kg for naphthoquine.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Simulation for patients weighing ≥70 kg.
Number of subjects: 29
Study: 35465803

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study: 35466039

Group type: EXPERIMENTAL
Intervention: One antipseudomonal class (e.g., beta-lactam)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Two antipseudomonal classes (e.g., beta-lactam/aminoglycoside)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Three or more antipseudomonal classes (e.g., beta-lactam/aminoglycoside/fluoroquinolone)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Multiple antipseudomonal classes
Number of subjects: 751
Study: 35466524

Group type: EXPERIMENTAL
Intervention: ADI-PEG20 (pegargiminase) combined with pemetrexed (500 mg/m²) and cisplatin (dosage not specified)
Number of subjects: 0
Study: 35466707

Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system placed on the arm
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system placed on the abdomen
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system for ages 2 to 6 years
Number of subjects: 155
Study: 35467123

Group type: EXPERIMENTAL
Intervention: Dik ≥ 2 model
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Dik ≥ 3 model
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Antonio > 1.225 model
Number of subjects: 461

Group type: COMPARATOR
Intervention: Antonio > 1.225 model vs. Dik ≥ 3 model
Number of subjects: 461
Study: 35467243

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (eftoza) 2.5-15 mg/kg intravenously on day 1 or day 1/day 8 every 21 days (dose-escalation phase)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (eftoza) 1.25-7.5 mg/kg once-weekly (QW) (dose-optimization phase)
Number of subjects: 105
Study: 35467434

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention
Number of subjects: 0
Study: 35467452

Group type: EXPERIMENTAL
Intervention: Lower-extremity revascularization (LER)
Number of subjects: 5614
Study: 35467562

Group type: EXPERIMENTAL
Intervention: pH monitoring after POEM
Number of subjects: 0
Study: 35467749

Group type: EXPERIMENTAL
Intervention: Selumetinib at 25 mg/m2 orally twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 0
Study: 35467818

Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) transplantation
Number of subjects: 335

Group type: COMPARATOR
Intervention: HLA-matched sibling donor (MSD) transplantation
Number of subjects: 335
Study: 35468269

Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 260

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 260
Study: 35468336

Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2 vaccine
Number of subjects: 11123

Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 vaccine
Number of subjects: 11123
Study: 35468618

Group type: EXPERIMENTAL
Intervention: CART-ddBCMA (100 × 10^6 or 300 × 10^6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CART-ddBCMA
Number of subjects: 13
Study: 35468680

Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting immune checkpoint proteins (CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy targeting checkpoint pathways
Number of subjects: 0